TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Offering Free Fruits and Vegetables to Men at Risk of Poverty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* income below 980 € per month~* \> 30 years of age~* living alone~* without regular food delivery service (except for e.g. meals on wheels once a day)~* born in Germany~* speaks German~Exclusion Criteria:~* lives in assisted living accommodations

- Gender: MALE
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Free Fruit and Vegetables (Type: EXPERIMENTAL): After baseline assessment of food intake patterns, the intervention will consist of providing free fruits and vegetables of their choice for a period of four weeks which will be provided fresh each week. At baseline and at the end of the 4-week period, a FFQ, two 24h-recalls and a questionnaire on consumed fruit and vegetable variety will be administered.
- Control Goup (Type: NO_INTERVENTION): At baseline and at the end of the 4-week period, a FFQ, four 24h-recalls and a questionnaire on consumed fruit and vegetable variety will be administered. At the end of the intervention period they receive once a basket of free fruits and vegetables.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: High (100mg) Versus Standard (60mg) Loading Dose of Prasugrel in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ST elevation myocardial infarction~* Pain onset \<12 hours~* Age \>18 and \<75 years~* Written informed consent~Exclusion Criteria:~* history of stroke/transient ischemic attack~* oral anticoagulation~* hemodynamic instability~* platelet count \<100000/μL~* hematocrit \<30%~* creatinine clearance \<30 ml/min~* severe hepatic dysfunction~* active bleeding~* weight \<60 Kg~* periprocedural IIb/IIIa inhibitor administration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Prasugrel 100mg loading dose (Type: EXPERIMENTAL): Prasugrel 100mg loading dose
- Prasugrel 60mg loading dose (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: FMT Delivered by Capsule Versus Colonoscopy for Recurrent C. Diff

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \> 18 and \< 90 years at the time of Screening.~2. Diagnosis of at least 3 episodes of recurrent CDI, with each episode defined as presence of diarrhea (\> 3 unformed stools/24 hours) associate with positive stool Clostridium difficle toxin, occurring within 3 months of each other.~3. CDI infection under symptomatic control with \< 3 loose/unformed BM's per 24 h period for at least 2 consecutive days before procedure.~4. Those with ability to provide informed consent.~Exclusion Criteria:~1. Those with complicated CDI, defined as white blood cell\>35 or \<0.5 x 109/L, significant abdominal pain and distension with evidence of toxic megacolon or pseudomembranous colitis, hypotension defined as systolic blood pressure \< 90 mmHg unresponsive to fluid resuscitation, end organ failure, or requiring intensive care unit admission.~2. Those with chronic diarrheal illness, such as irritable bowel syndrome or inflammatory bowel disease unless they are in remission for at least 3 months prior to enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Delivery via capsule (Type: EXPERIMENTAL): Fecal microbiota transplant is delivered by oral capsules
- Delivery via colonoscopy (Type: EXPERIMENTAL): Fecal microbiota transplant delivered by colonoscopy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Must understand and voluntarily sign an informed consent form~* Age 18 years at the time of signing the informed consent form~* Documented diagnosis of myelodysplastic syndromes (MDS) that meets International Prognostic Scoring System (IPSS) criteria for low to intermediate-1-risk disease and has an associated del 5q(31) cytogenetic abnormality~* Red blood cell (RBC) transfusion dependent anaemia defined as not having any 56 days without a RBC transfusion within at least the immediate 112 days~* Must be able to adhere to the study visit schedule and other protocol requirements~* Women of childbearing potential must have a negative pregnancy test prior to inclusion~Exclusion Criteria:~* Pregnant or lactating females~* Prior therapy with lenalidomide~* Proliferative (white blood cell (WBC)= 12,000/mL) chronic myelomonocytic leukemia (CMML)~* Prior \>= grade-2 (using the National Cancer Institute (NCI)'s Common Terminology Criteria for AEs (CTCAE) (v 3.0)) allergic reaction to thalidomide~* Prior desquamating (blistering) rash while taking thalidomide~* Prior history of malignancy other than MDS (except basal cell or squamous cell carcinoma or carcinoma in situ of the cervix or breast) unless the subject has been free of disease for \>3 years~* Use of cytotoxic chemotherapeutic agents or experimental agents (agents that are not commercially available) for the treatment of MDS within 28 days~* Less than 6 months since prior allogeneic bone marrow transplantation~* Less than 3 months since prior autologous bone marrow or stem cell transplantation~* Less than 28 days since prior myelosuppressive anticancer biologic therapy~* Recombinant human erythropoietin (rHuEPO) therapy received within 28 days~* Known human immunodeficiency virus (HIV-1) positivity~* Any serious medical condition or psychiatric illness that will prevent the subject from signing the informed consent form or will place the subject at unacceptable risk if he or she participates in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo matching to active study arms.
- Lenalidomide 5 mg (Type: EXPERIMENTAL): Lenalidomide 5 mg daily 28/28 days
- Lenalidomide 10 mg (Type: EXPERIMENTAL): Lenalidomide 10 mg daily 21/28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: txt2protect: Using Text Messaging to Increase HPV Vaccination Among Young Sexual Minority Men

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~Participants must:~1. Be male (sex at birth and gender identity)~2. Self-identify as gay, bisexual, or queer; ever had sex with a man; or be physically attracted to men~3. Be English speaking~4. Live in the Chicago metro area~5. Be the exclusive owner of a cell phone~6. Have used text messaging for at least 6 months~7. Plan to have the same cell phone number for the next 9 months~8. Be enrolled in an unlimited text messaging plan~Exclusion Criteria~* Participants must not have been previously vaccinated for HPV.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 25 Years
- Healthy Volunteers: t

Study Arms:
- txt2protect (Type: EXPERIMENTAL): Content was delivered in 2 phases over 36 weeks. During Phase 1 (weeks 1-3), participants received 10-12 messages daily. During Phase 2 (weeks 4-36), message frequency decreased to monthly messages. Phase 1 content was presented in 3 modules. Module 1 addressed information about HPV infection and HPV vaccination. Module 2 addressed motivation to receive HPV vaccine. Module 3 addressed behavioral skills and self-efficacy for initiating and completing the 3-dose series (e.g., talking with their doctor about the vaccine). Phase 2 booster messages largely reinforced Phase 1 content to foster continued engagement with the program.~txt2protect: Text messages sharing HIV/STI prevention information with a focus on HPV infection and vaccination.
- Sexual Health Control (Type: ACTIVE_COMPARATOR): Content was delivered in 2 phases over 36 weeks. During Phase 1 (weeks 1-3), participants received 10-12 messages daily. During Phase 2 (weeks 4-36), message frequency decreased to monthly messages. Phase 1 content was presented in 3 modules; however, unlike the treatment group, content was topic-based rather than theory-based and focused on general sexual health. Module 1 addressed basic facts about HIV and sexually transmitted infections (STI), including HPV. Module 2 addressed HIV/STI prevention (e.g., condom use, PrEP) and will included basic facts about HPV vaccination currently available online. Module 3 addressed tips for healthy relationships. Phase 2 booster messages largely reinforced Phase 1 content to foster continued engagement with the program.~Sexual Health Control: Text messages sharing HIV/STI prevention and healthy relationship building information, including information about HPV infection and vaccination.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Weekly Dosing of Malarone ® for Prevention of Malaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A male or non-pregnant, non-lactating female 18 to 50 years of age (inclusive) at the time of screening~* Free of clinically significant health problems~* Baseline ECG before entering into the study~* Available to participate for duration of study (approximately 4 months, not including screening period)~* If the participant is female, not pregnant or lactating and willing to use contraception to prevent pregnancy~* BMI between 19 and 30~Exclusion Criteria:~* History of malaria or travel to a malarious country within the previous 12 months~* History of participation in a study in which potential exposure to malaria or vaccination against malaria occurred.~* Planned travel to malarious areas during the study period.~* History of malaria chemoprophylaxis within 60 days prior to time of study entry.~* Chronic use of antibiotics with anti-malarial effects~* Chronic use (defined as more than 14 days)of immunosuppressants or other immune-modifying drugs within six months of study entry.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection~* Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination, ECG or laboratory screening tests~* Significant unexplained anemia~* History of sickle cell disease or sickle cell trait~* Seropositive for hepatitis B or hepatitis C~* History of splenectomy~* Pregnant or lactating female, or female who intends to become pregnant during the study~* Suspected or known current alcohol abuse as defined by the American Psychiatric Association in DSM IV~* History of a neuropsychiatric disorder (anxiety, depression, psychosis, schizophrenia)~* Chronic or active illicit and/or intravenous drug use~* History of allergy to atovaquone, proguanil or chloroquine~* History of psoriasis~* Concurrent participation in other research studies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Drug (Type: EXPERIMENTAL): 5 groups, each group receiving Malarone tablet(s) (250/100mg)prior to challenge.~Group 1 - 1 tablet 1 day before challenge Group 2 - 1 tablet 4 days before challenge Group 3 - 1 tablet 7 days before challenge Group 4 - 2 tablets 7 days before challenge Group 5 - 4 tablets 7 days before challenge
- Control -no prophylaxis (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Select Inclusion Criteria:~1. Histological or cytological diagnosis of HCC.~2. The subject has disease that is not amenable to a curative treatment approach.~3. Received prior sorafenib.~4. Progression following at least 1 prior systemic treatment for HCC.~5. Recovery to from toxicities related to any prior treatments.~6. ECOG performance status of 0 or 1.~7. Adequate hematologic and renal function, based upon meeting protocol defined laboratory criteria within 7 days before randomization.~8. Child-Pugh Score of A.~9. Antiviral therapy per local standard of care if active hepatitis B (HBV) infection.~10. Sexually active fertile subjects(male and female)must agree to use medically accepted methods of contraception during the course of the study and for 4 months after the last dose of study treatment.~11. Female subjects of childbearing potential must not be pregnant at screening.~Select Exclusion Criteria:~1. Fibrolamellar carcinoma or mixed hepatocellular cholangiocarcinoma.~2. Receipt of more than 2 prior systemic therapies for advanced HCC.~3. Any type of anticancer agent (including investigational) within 2 weeks before randomization.~4. Radiation therapy within 4 weeks (2 weeks for radiation for bone metastases) or radionuclide treatment within 6 weeks of randomization.~5. Prior cabozantinib treatment.~6. Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery and stable for at least 3 months before randomization.~7. Concomitant anticoagulation, at therapeutic doses, with anticoagulants.~8. Serious illness other than cancer that would preclude safe participation in the study.~9. Subjects with untreated or incompletely treated varices with bleeding or high risk for bleeding.~10. Moderate or severe ascites.~11. Pregnant or lactating females.~12. Diagnosis of another malignancy within 2 years before randomization, except for superficial skin cancers, or localized, low-grade tumors.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cabozantinib (XL184) (Type: EXPERIMENTAL): Cabozantinib (XL184) 60 mg tablet once daily
- Placebo (Type: PLACEBO_COMPARATOR): Oral cabozantinib-matched placebo tablet once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Agents.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>=18 years of age;~* active rheumatoid arthritis;~* receiving outpatient treatment;~* an inadequate response, or intolerance, to \>=1 anti-TNF agent.~Exclusion Criteria:~* other rheumatic autoimmune disease or inflammatory joint disease;~* concurrent treatment with any anti-TNF-alpha therapy;~* joint or osseous surgery during 8 weeks prior to recruitment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Documented history of migraine in the 12 months prior to screen~* 4-14 days per month of migraine symptoms~* \>=80% diary compliance during the Baseline period~* Failure of previous migraine prophylactic treatments~Exclusion Criteria:~* \>50 years old at migraine onset~* Pregnant or nursing~* History of cluster or hemiplegic headache~* Evidence of seizure or psychiatric disorder~* Score of over 19 on Beck Depression Inventory-2~* Active chronic pain syndrome~* Cardiac or hepatic disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo DB (Type: PLACEBO_COMPARATOR): Matching placebo subcutaneous injections administered every 4 weeks during Double-Blind Epoch
- AMG334 140 mg DB (Type: EXPERIMENTAL): AMG334 70 mg subcutaneous injections (2) administered every 4 weeks during Double-Blind Epoch
- AMG334 140 mg DB cont on AMG334 140 mg (Type: EXPERIMENTAL): AMG334 70 mg subcutaneous injections (2) during DB continued on AMG334 140 mg in Open-Label Epoch
- Placebo in DB to AMG334 140 mg (Type: EXPERIMENTAL): Placebo in Double-Blind Epoch (DB) switched to AMG334 140 mg in Open-Label Epoch

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacogenomic Evaluation of Antihypertensive Responses

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~An average seated home diastolic blood pressure (DBP) \> 85 mmHg and home systolic blood pressure (SBP) \< 180 mmHg. Subjects must also have an average seated (\> 5 minutes) clinic DBP between 90 mmHg and 110 mmHg and SBP \< 180 mmHg~Exclusion Criteria:~secondary forms of HTN, patients currently treated with three or more antihypertensive drugs, isolated systolic HTN, other diseases requiring treatment with BP lowering medications, heart rate \< 55 beats/min, known cardiovascular disease (including history of angina pectoris, heart failure, presence of a cardiac pacemaker, history of myocardial infarction or revascularization procedure, or cerebrovascular disease, including stroke and TIA), diabetes mellitus (Type 1 or 2), renal insufficiency (serum creatinine \> 1.5 in men or 1.4 in women), primary renal disease, pregnancy or lactation, liver enzymes \> 2.5 upper limits of normal, current treatment with NSAIDS, cyclooxygenase-2 (COX2) inhibitors, oral contraceptives or estrogen.

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Atenolol (Type: EXPERIMENTAL): atenolol 50 mg, then 100 mg if BP \< 120/70, then add HCTZ 12.5 mg if BP \< 120/70, then HCTZ 25 mg if BP \< 120/70
- Hydrochlorothiazide (HCTZ) (Type: EXPERIMENTAL): HCTZ 12.5 mg then HCTZ 25 mg if BP \< 120/70, then add atenolol 50 mg if BP \< 120/70, then atenolol 100 mg if BP \< 120/70.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Symptom Response in Normal and Dry Eye Patients Secondary to Application of a Menthol-Containing Eyedrop (Rohto® Hydra)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Be male or female of any race, at least 18 years of age at Visit 1.~2. Have provided verbal and written informed consent.~3. Have a best corrected visual acuity of +0.70 logMAR or better in both eyes at Visit 1, as assessed by Early Treatment of Diabetic Retinopathy Study (ETDRS) chart.~4. Qualify for exactly one of the three cohorts.~Exclusion Criteria:~1. Have any contraindications to the use of Systane® Ultra, or Rohto® Hyrda, or its components (including Menthol).~2. Have a known allergy to the study medications or their components.~3. Have any clinically significant slit lamp findings at Visit 1, including active blepharitis, meibomian gland dysfunction (MGD), lid margin inflammation or ocular allergies that requires therapeutic treatment and/or, in the opinion of the investigator, may interfere with the study parameters.~4. Be diagnosed with an ongoing ocular infection (bacterial, viral or fungal), or active ocular inflammation (e.g., follicular conjunctivitis) at Visit 1.~5. Have a history of laser in situ keratomileusis (LASIK) surgery in either eye.~6. Have had any ocular surgical procedure within 12 months prior to Visit 1.~7. Have used contact lenses within 30 days prior to Visit 1 and for the duration of the study.~8. Have used any topical ocular prescription (including medications for glaucoma) or over-the-counter (OTC) solutions, artificial tear substitutes, gels or scrubs within 24 hours prior to Visit 1 and for the duration of the study, except for the study drops.~9. Have an uncontrolled systemic disease.~10. Be a woman who is pregnant, nursing an infant, or planning a pregnancy.~11. Have a condition or is in a situation that, in the opinion of the investigator, may put the patient at significant risk, may confound the study results, or may interfere significantly with the patients' participation in the study.~12. Be currently enrolled in an investigational drug or device study or have used an investigational drug or device within 30 days prior to Visit 1.~13. Currently have any punctal occlusions in either eye.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Rohto (r) Hydra (Type: ACTIVE_COMPARATOR): Menthol containing over the counter eyedrop
- Systane (r) Ultra (Type: PLACEBO_COMPARATOR): Non-Menthol containing over the counter eyedrop

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete